The ever increasing complexity of regulations and drug approval pathways has converted regulatory intelligence into one of the key assets during any kind of drug development.
Brexit updates for human use medicinal products approved via MRP/DCP
As Brexit is quickly coming closer, the CMDh has published an updated version of the Practical guidance for procedures related to Brexit for medicinal products for human use approved via MRP/DCP in December 2020.